passagebio.comPassage Bio, Inc. - Home
passagebio.com Profile
passagebio.com is a domain
that was created on 2017-03-20,making it 7 years ago.
It has several subdomains, such as investors.passagebio.com , among others.
Description：Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their...
Discover passagebio.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
passagebio.com Information
| HomePage size: 65.316 KB |
| Page Load Time: 0.137573 Seconds |
| Website IP Address: 162.159.129.11 |
passagebio.com Similar Website
| Fact Sider - Celebrity Bio, Facts, Family, Photos, Career |
| Official bio.fm Blog |
| My account – QCNet | Bio-Rad |
| Bio-Rad Laboratories, Inc. - Investor Relations |
| BIO/Manetas Timeline/2023 |
| Biospecimen Collection | Sanguine Bio |
| Pharma-Bio Serv New Employee Documents Home |
| BIO-key Blog |
| Life Science Marketing | Bitesize Bio Content Marketing |
| American Bio-Clinical Laboratories |
| Passage Bio, Inc. - Investors and News - Overview |
| Business Solutions®, BIO's Cost Savings Program | BIO |
| The #1 Link In Bio Tool for Social Media - Sell on Instagram with Bio Link |
passagebio.com PopUrls
| Passage Bio, Inc. - Home https://www.passagebio.com/home/default.aspx |
| Passage Bio, Inc. - Contact https://www.passagebio.com/contact/ |
| Pipeline - Overview https://www.passagebio.com/pipeline/overview-1/ |
| Careers https://www.passagebio.com/careers/default.aspx |
| Investors and News - Resources https://www.passagebio.com/investors-and-news/resources/ |
| Our Company - Our Team https://www.passagebio.com/our-company/our-team/ |
| Our Company - Who We Are https://www.passagebio.com/our-company/who-we-are/ |
| Investor FAQs https://www.passagebio.com/investors-and-news/investor-faqs/ |
| GM1 Gangliosidosis https://www.passagebio.com/pipeline/gm1-gangliosidosis/default.aspx |
| Passage Bio, Inc. - Our Company - Who We Are https://www.passagebio.com/our-company/who-we-are/default.aspx |
| Passage Bio, Inc. - Investors and News - Overview https://www.passagebio.com/investors-and-news/overview/default.aspx |
| Press Releases and Statements - Passage Bio https://www.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2021/Passage-Bio-Announces-Pipeline-Expansion-and-Clinical-Pr |
| Press Releases and Statements - Passage Bio https://www.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2022/Passage-Bio-Doses-First-Patient-in-Global-Clinical-Trial |
| Passage Bio, Inc. - FDA Clears IND Application for Passage Bio’s … https://investors.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2021/FDA-Clears-IND-Application-for-Passage-Bios-Gene-T |
| Passage Bio, Inc. - Our Science - Our Approach https://www.passagebio.com/our-science/our-approach/default.aspx |
passagebio.com DNS
| A passagebio.com. 1800 IN A 162.159.129.11 |
| MX passagebio.com. 1800 IN MX 10 us-smtp-inbound-1.mimecast.com. |
| NS passagebio.com. 3600 IN NS ns63.domaincontrol.com. |
| TXT passagebio.com. 1800 IN TXT 0ed1fe018a3170ab2a6e944b8cbb7755ef7810b432 |
| SOA passagebio.com. 3600 IN SOA ns63.domaincontrol.com. dns.jomax.net. 2024031101 28800 7200 604800 600 |
passagebio.com Httpheader
| Date: Mon, 13 May 2024 03:59:48 GMT |
| Content-Type: text/html; charset=utf-8 |
| Transfer-Encoding: chunked |
| Connection: keep-alive |
| CF-Ray: 882fbce6fda52a91-LAX |
| CF-Cache-Status: REVALIDATED |
| Cache-Control: public, max-age=10, stale-if-error=86400, stale-while-revalidate=86400 |
| Last-Modified: Mon, 13 May 2024 03:59:48 GMT |
| Strict-Transport-Security: max-age=31536000; includeSubDomains |
| Vary: Accept-Encoding |
| X-Content-Type-Options: nosniff |
| X-Frame-Options: SAMEORIGIN |
| X-XSS-Protection: 1; mode=block |
| Server: cloudflare |
passagebio.com Meta Info
| content="text/html; charset=utf-8" http-equiv="Content-type"/ |
| content="RevealTrans(Duration=0,Transition=0)" http-equiv="Page-Enter"/ |
| content="IE=edge,chrome=1" http-equiv="X-UA-Compatible"/ |
| content="width=device-width, initial-scale=1" name="viewport"/ |
| content="default-src 'self' https: http: 'unsafe-inline' 'unsafe-eval' *.q4inc.com; script-src 'self' *.cloudfront.net *.pusherapp.com *.newrelic.com *.nr-data.net *.twitter.com *.platform.twitter.com *.cdn.syndication.twimg.com *.twimg.com *.bugherd.com *.q4cdn.com *.q4web.com *.amazonaws.com *.highcharts.com *.googletagmanager.com *.googleadservices.com *.google-analytics.com *.google.com *.gstatic.com *.q4app.com *.pendo.io *.ads-twitter.com *.licdn.com *.facebook.net 'unsafe-inline' 'unsafe-eval' *.q4inc.com" http-equiv="Content-Security-Policy"/ |
| content="9qpNu15GYXo5NF5CjUdVU9QSiK4GckrK-y5oB8QSlkE" name="google-site-verification"/ |
| content="https://s27.q4cdn.com/477254652/files/design/PassageBioSocialImage.png" property="og:image"/ |
| content="https://s27.q4cdn.com/477254652/files/design/PassageBioSocialImage.png" name="twitter:image"/ |
| content="vt3at7mvnj2pqzo5avt2ufc7ptnyqw" name="facebook-domain-verification"/ |
| content="Home | Passage Bio" property="og:title"/ |
| content="Home | Passage Bio " name="title"/ |
| content="https://www.passagebio.com/" property="OG:URL"/ |
| content="https://www.passagebio.com/" name="url"/ |
| content="Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families." property="og:description"/ |
| content="Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families." name="description"/ |
passagebio.com Html To Plain Text
Our Company Who We Are Our Team Our Science Our Approach Role of Progranulin Manufacturing Pipeline Overview Frontotemporal Dementia GM1 Gangliosidosis Patients and Caregivers Our Commitment Compassionate Use Statement Community Resources Investors and News Overview News Events and Presentations Financials and Filings Stock Information Investor FAQs Resources Corporate Governance Inquiries and Alerts Careers Contact Toggle Site Search Search query Search query Our Company Who We Are Our Team Our Science Our Approach Role of Progranulin Manufacturing Pipeline Overview Frontotemporal Dementia GM1 Gangliosidosis Patients and Caregivers Our Commitment Compassionate Use Statement Community Resources Investors and News Overview News Events and Presentations Financials and Filings Stock Information Investor FAQs Resources Corporate Governance Inquiries and Alerts Careers Contact un known. The power of gene therapy can change more than words. It can transform the future. Our Company Our Science Patients and CaregiversAt Passage Bio, our mission is to improve the lives of patients with neurodegenerative diseases by delivering genetic medicines that will permanently redefine the course of their conditions. Fulfilling the promise of genetic medicine by developing transformative therapies for people with devastating CNS diseases.Learn more about our company Your browser does not support HTML5 video.Advancing Lead Clinical Programs in Neurodegenerative DiseasesOur Phase 1/2 Study in Frontotemporal Dementia (FTD) The upliFT-D study is a multinational Phase 1/2 clinical trial evaluating the safety and efficacy of PBFT02, a novel and potentially transformative gene therapy for patients with FTD with progranulin gene mutations. Learn about PBFT02Our Phase 1/2 Study in GM1 Gangliosidosis (GM1) The Imagine-1 study is a multinational Phase 1/2 clinical trial evaluating the safety and efficacy of PBGM01, a novel and potentially transformative gene therapy for patients with infantile GM1 gangliosidosis. Learn about PBGM01Read the latest news about Passage Bio Improving the Lives of People Affected by CNS Diseases People living or born with CNS diseases are at the center of every decision we make. We strive to turn disbelief into belief, disease into ease, and the incurable into the curable. That’s what it means to protect patients and their families against loss in neurodegenerative diseases. Learn about our commitment CONTACT US | PRIVACY POLICY | SITE MAP | UnsubscribePRIVACY POLICY | SITE MAP The information on this website is intended for use by US residents only. © Passage Bio. All Rights Reserved. FOLLOW US Facebook (Opens in new window) Twitter (Opens in new window) Linkedin (Opens in new window) The information on this website is intended for use by US residents only. © Passage Bio. All Rights Reserved. Powered By Q4 Inc. 5.122.0.3 (opens in new...
passagebio.com Whois
Domain Name: PASSAGEBIO.COM Registry Domain ID: 2106481126_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2022-10-16T11:32:50Z Creation Date: 2017-03-20T15:43:02Z Registry Expiry Date: 2027-03-20T15:43:02Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS63.DOMAINCONTROL.COM Name Server: NS64.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T17:55:12Z <<<